Fertility Preservation Iatrogenic denied due to quantity / dose limits by Aetna?

Aetna's specific coverage criteria for FERTILITY PRESERVATION IATROGENIC are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Fertility Preservation (Iatrogenic) Under "Quantity Limits"

Aetna may impose quantity or frequency limits on fertility-preservation services — for example, limiting the number of oocyte retrieval cycles, the number of embryos that may be cryopreserved under a single authorization, or the duration of cryostorage covered. When the treating reproductive endocrinologist determines that a single cycle is unlikely to yield sufficient viable gametes or embryos — particularly for patients whose ovarian reserve has already been affected by illness or prior treatment — a quantity-limits denial can directly conflict with individualized medical judgment.

## Why This Denial Is Appealable

Quantity limits in coverage policies must have a clinical basis and must be applied with room for individual medical necessity exceptions. When a prescriber documents that the standard covered quantity is medically insufficient for a specific patient — based on their diagnosis, age, ovarian reserve assessment, and clinical circumstances — that documentation creates a strong basis for an exception appeal. A one-size-fits-all quantity limit applied without regard to individual clinical need may also raise parity concerns if the plan covers analogous reproductive services without equivalent limits.

## Federal Appeal Framework

• Internal appeal: File under ERISA §503 or ACA §2719. Request a copy of the specific quantity-limit criterion that applies to your benefit category.
• External review: After internal denial, request IRO review within approximately four months. Provide the IRO with the treating physician's individualized clinical rationale.
• Expedited review: If the additional cycle or quantity is needed before gonadotoxic treatment begins, request expedited processing with a physician attestation of time-sensitivity.

## Documentation to Gather

• Ovarian reserve and fertility workup: All relevant diagnostic findings from your reproductive endocrinologist supporting the need for the quantity requested.
• Prior cycle outcomes: If a prior covered cycle was completed, document the outcome (e.g., number of viable oocytes or embryos retrieved) and the physician's explanation for why additional cycles are medically necessary.
• Prescriber medical-necessity letter: A detailed letter from your reproductive endocrinologist explaining, with reference to ASRM practice guidelines and your specific clinical parameters, why the quantity limit is medically inadequate for your case.
• Oncology treatment timeline: Documentation confirming the window available before gonadotoxic treatment, reinforcing why all necessary cycles must occur within that window.
• Aetna's coverage policy: Obtain the exact quantity-limit language from Aetna's published policy and confirm whether it includes a medical-necessity exception process.

## Criteria-Mapping Structure

Construct a table in your appeal:

| Aetna Quantity Criterion | Source | Your Clinical Facts | |---|---|---| | [Verbatim limit language] | [Policy name/section] | [Physician finding, date, chart reference] |

In the narrative, cite the applicable ASRM guideline organization's position on individualized cycle planning. Request that Aetna's physician reviewer contact your treating reproductive endocrinologist directly. Document that the requested quantity is consistent with what the FDA-approved prescribing information (for any stimulation agents used) and ASRM guidance support for patients with your clinical profile.